Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer subpoenaed in...

    Pfizer subpoenaed in US intravenous saline solution probe

    Written by supriya kashyap kashyap Published On 2017-04-21T11:02:47+05:30  |  Updated On 21 April 2017 11:02 AM IST
    Pfizer subpoenaed in US intravenous saline solution probe

    Boston : Pfizer Inc has received grand jury subpoenas from the U.S. Justice Department in connection with an antitrust investigation focusing on drug makers that market intravenous saline solutions.


    The drug maker disclosed the subpoenas in a statement after ICU Medical Inc, which recently acquired Pfizer's global infusion therapy business, and Baxter International Inc said they received similar subpoenas.


    ICU Medical said the probe related to Hospira Infusion Systems, which it purchased in February from Pfizer, which in turn acquired it in a merger with Hospira Inc in 2015.


    "Pfizer can confirm that it has received grand jury subpoenas in connection with an investigation by the U.S. Department of Justice, Antitrust Division and we are evaluating the requests," Pfizer said.


    A Pfizer spokeswoman said the probe related to intravenous saline solutions. The Justice Department declined to comment.


    The probe comes amid a shortage of intravenous saline solutions commonly used to hydrate hospital patients that dates back to late 2013, when drug companies began notifying hospitals that they might experience delivery delays.


    The U.S. Food and Drug Administration in January 2014 added the solutions to its drug shortage list, at the time saying the shortage was triggered by factors including increased hospital demand, potentially related to the flu season.


    In 2015, a bipartisan group of four U.S. senators asked the Federal Trade Commission to probe three companies they said supplied all the saline solution used in the United States, Baxter, Hospira and B. Braun.


    They said that since the shortage began, prices had risen 200 percent to 300 percent.


    Democratic Senator Richard Blumenthal of Connecticut, one of the four senators, on Wednesday called the Justice Department's probe "an important step toward getting to the bottom of any possible illegal collusion by saline solution manufacturers."


    On Friday, Baxter said one of its employees received a grand jury subpoena issued by the U.S. District Court for the Eastern District of Pennsylvania. ICU Medical on Tuesday said it received a similar subpoena.


    ICU Medical and Baxter said the subpoenas sought documents and testimony about the manufacturing, selling, pricing and shortages of intravenous solutions, including saline, and communications with competitors.


    Baxter and ICU Medical have said they are cooperating with the probe and that they have also received information requests from New York Attorney General Eric Schneiderman.


    Baxter and Hospira also face a proposed class action lawsuit accusing them of conspiring to fix prices for intravenous saline solution.

    BaxterEastern District of Pennsylvaniaglobal infusion therapyhospiraintravenous saline solutionPfizerRichard Blumenthal
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok